8/8/2023 0 Comments Keynote 407![]() ![]() Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. 10.1016/S0140-6736(14)60845-Xīorghaei H, Paz-Ares L, Horn L, et al. This retrospective study examined real-world time on treatment (rwToT) and overall survival (OS) among patients with advanced squamous NSCLC treated with first-line pembrolizumab-chemotherapy at oncology practices in the United States. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer Transl Lung Cancer Res. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The evidence supporting this protocol is provided by a phase 3 multicentre international randomised trial (KEYNOTE-407) involving 559 patients comparing. ![]() Kowalski, MD, PhD2 Alexander Luft, MD, PhD3 Mahmut Gm, MD4 David Vicente, MD5 Julien Mazires, MD, PhD6. Schiller JH, Harrington D, Belani CP, et al. Pembrolizumab Plus Chemotherapy in Squamous NonSmall-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study Silvia Novello, MD, PhD1 Dariusz M. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. The robust positive results of Keynote-407 have led to both FDA (3) and EMA (4) approvals of pembrolizumab combined with carboplatin and paclitaxel/nab. ![]() Cetin K, Ettinger DS, Hei Y, O’Malley CD. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |